2024-03-28T10:16:03Zhttp://repisalud.isciii.es/oai/requestoai:repisalud.isciii.es:20.500.12105/143162023-08-31T08:20:37Zcom_20.500.12105_15322com_20.500.12105_2051com_20.500.12105_2060com_20.500.12105_2052col_20.500.12105_16963col_20.500.12105_16938col_20.500.12105_2061
Repisalud
author
Valle-Millares, Daniel
author
Brochado-Kith, Oscar
author
Martín-Carbonero, Luz
author
Domínguez-Domínguez, Lourdes
author
Ryan, Pablo
author
De Los Santos, Ignacio
author
De la Fuente, Sara
author
Castro, Juan M
author
Lagarde, María
author
Cuevas, Guillermo
author
Mayoral-Muñoz, Mario
author
Matarranz, Mariano
author
Díez, Victorino
author
Gomez-Sanz, Alicia
author
Martinez-Roman, Paula
author
Crespo-Bermejo, Celia
author
Palladino, Claudia
author
Muñoz-Muñoz, María
author
Jimenez-Sousa, Maria Angeles
author
Resino, Salvador
author
Briz, Veronica
author
Fernandez-Rodriguez, Amanda
author
Multidisciplinary Group of Viral Coinfection HIV/Hepatitis (COVIHEP)
funder
Instituto de Salud Carlos III
funder
Fundación Universidad Alfonso X el Sabio
funder
Fundación Banco Santander
funder
Red de Investigación Cooperativa en Investigación en Sida (España)
funder
Centro de Investigación Biomédica en Red - CIBERINFEC (Enfermedades Infecciosas)
2022-05-09T07:41:05Z
2022-05-09T07:41:05Z
2021-11-05
Biomedicines. 2021 Nov 5;9(11):1627.
2227-9059
http://hdl.handle.net/20.500.12105/14316
34829855
10.3390/biomedicines9111627
Biomedicines
Micro RNAs (miRNAs) are essential players in HIV and HCV infections, as both viruses modulate cellular miRNAs and interact with the miRNA-mediated host response. We aim to analyze the miRNA profile of HIV patients with different exposure to HCV to explore specific signatures in the miRNA profile of PBMCs for each type of infection. We massively sequenced small RNAs of PBMCs from 117 HIV+ infected patients: 45 HIV+ patients chronically infected with HCV (HIV/HCV+), 36 HIV+ that spontaneously clarified HCV after acute infection (HIV/HCV-) and 36 HIV+ patients without previous HCV infection (HIV). Thirty-two healthy patients were used as healthy controls (HC). Differential expression analysis showed significantly differentially expressed (SDE) miRNAs in HIV/HCV+ (n = 153), HIV/HCV- (n = 169) and HIV (n = 153) patients. We found putative dysregulated pathways, such as infectious-related and PI3K signaling pathways, common in all contrasts. Specifically, putatively targeted genes involved in antifolate resistance (HIV/HV+), cancer-related pathways (HIV/HCV-) and HIF-signaling (HIV) were identified, among others. Our findings revealed that HCV strongly influences the expression profile of PBMCs from HIV patients through the disruption of its miRNome. Thus, different HCV exposure can be identified by specific miRNA signatures in PBMCs.
eng
HCV
HIV
High throughput sequence
MicroRNAs
Spontaneous viral clearance
Different HCV Exposure Drives Specific miRNA Profile in PBMCs of HIV Patients
journal article
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
URL
https://repisalud.isciii.es/bitstream/20.500.12105/14316/1/DifferentHCVExposureDrives_2021.pdf
File
MD5
35d772b147c4f33cc5f2b7f95af94548
1750888
application/pdf
DifferentHCVExposureDrives_2021.pdf
URL
https://repisalud.isciii.es/bitstream/20.500.12105/14316/2/DifferentHCVExposureDrivesSupplementaryMaterials_2021.pdf
File
MD5
65cd7e39044b944171e24ad05cbf0f90
429981
application/pdf
DifferentHCVExposureDrivesSupplementaryMaterials_2021.pdf
URL
https://repisalud.isciii.es/bitstream/20.500.12105/14316/5/DifferentHCVExposureDrives_2021.pdf.txt
File
MD5
90d2477fdfd186afd5520b7f589ef30c
69077
text/plain
DifferentHCVExposureDrives_2021.pdf.txt
URL
https://repisalud.isciii.es/bitstream/20.500.12105/14316/7/DifferentHCVExposureDrivesSupplementaryMaterials_2021.pdf.txt
File
MD5
50f44460ee958769a212dcaf0c4ae610
41651
text/plain
DifferentHCVExposureDrivesSupplementaryMaterials_2021.pdf.txt